Parallel to the development of the Reithera vaccine and "in the framework of an effort stimulated and supported also by the Italian Government to make the production capacity of vaccines in our country wider and more solid, Reithera can provide its know-how and production capacity for respond positively to any requests for the production of one of the Covid-19 vaccines already approved (mRna and adenovirus type) and also distributed in Italy, both at the Castel Romano site and through external collaborations, as has been done for some time for other vaccines " . The company itself communicates it. "As evidence of the strong commitment in the development of its GRAd-COV2 vaccine, they explain, the Company has already invested in theexpansion of the Castel Romano pharmaceutical plant through the construction of a new large-scale production area equipped with bioreactors with a total capacity of 3000 liters with an annual production potential of between 50 and 100 million doses "." ReiThera, moreover, has by vocation and business model, the production of biopharmaceutical products for third parties. One of the main collaborators of ReiThera - concludes the group - is the Sabin Vaccine Institute, a US non-profit organization that is developing and producing the Ebola vaccine in its Roman facility.has as its vocation and business model the production of biopharmaceutical products for third parties. One of the main collaborators of ReiThera - concludes the group - is the Sabin Vaccine Institute, a US non-profit organization that is developing and producing the Ebola vaccine in its Roman facility.has as its vocation and business model the production of biopharmaceutical products for third parties. One of the main collaborators of ReiThera - concludes the group - is the Sabin Vaccine Institute, a US non-profit organization that is developing and producing the Ebola vaccine in its Roman facility.
Phase 3 could end after the summer
- Reithera confirms that it is strongly committed to phase 2-3 of the clinical trial, launched last month, of the GRAd-COV2 vaccine against COVID-19 based on the proprietary technology of the gorilla isolated adenovirus, a technology similar to that of other vaccines already approved by the European Medicines Agency (EMA) and, if the trial proceeds according to plan, we expect to complete it after the summer ". This is what the President of Reithera Antonella Folgori declares in a note, underlining that" the design of the phase 3 study will have to adapt to a rapidly evolving health, epidemiological and social context and ReiThera will make use of the opinion and guidelines dictated by regulatory agencies. "" The experimentation is proceeding at full speed - underlines Folgori - with thegoal of continuing the development of the GRAd-COV2 vaccine. We found a strong adhesion and participation in the phase 2 study, thanks to the commitment of the numerous clinical centers and experimenters involved, the support of Invitalia and INMI Spallanzani, in addition to the dedication of the ReiThera team ". The enrollment of 900 volunteers - he continues - it was in fact completed in a few days, and the vaccination as well as the monitoring of the volunteers are proceeding as per protocol in the 26 clinical centers throughout the national territory. The preliminary safety and immunogenicity data generated in the first weeks after vaccination - concludes the President - will be evaluated by an independent committee in order to promote the expansion to the next phase 3 ".